Having trouble accessing articles? Reset your cache.

Fidaxomicin: Additional Phase III data

Pooled data from a pair of double-blind Phase III trials in 1,164 patients showed that in patients with a recurrent episode of CDI within 3

Read the full 253 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE